Interestingly, despite their reported therapeutic effectiveness in neurodegenerative diseases such as MS, targeting S1P signalling cascades via its downstream receptors displayed adverse phenotypes that were not observed in SPL knockout mice in which S1P expression was elevated. Here, SGPL1 is linked to myeloid sarcoma.